Eli Lilly (LLY -0.6%) stops developing its Tabalumab drug to treat rheumatoid arthritis almost...

|About: Eli Lilly and Company (LLY)|By:, SA News Editor

Eli Lilly (LLY -0.6%) stops developing its Tabalumab drug to treat rheumatoid arthritis almost two months after data from a Phase III study demonstrated that the medicine would probably not be effective. However, Lilly will continue late-stage testing of Tabalumab in patients with an auto-immune disorder called systemic lupus erythematosus, and Phase II trials for multiple myeloma. (PR)